References
- ICH reflection paper-proposed ICH guideline work to advance Patient Focused drug Development (PFDD); 24 June 2021. EMA/CHMP/ICH/338534/2021
- 2.Simo TA, Khouri MS, Kou TD, et al. Realizing the potential of the patient perspective. PPA. 2020;14:2001–2007.
- Mitrovic D, Folkeringa R, Veeger N, et al. Reasons for discontinuation of novel oral anticoagulation therapy in patients with atrial fibrillation. Curr Med Res Opin. 2020;36(4):547–553.
- Landelijke Standard Keten Antistolling 2.0 voor de eerste- en tweedelijns zorg. Kennis instituut van Medisch Specialisten 2014.
- Kaatz S, Ahmad D, Spyropoulos AC, Subcommittee on Control of Anticoagulation, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–2126.
- Piersma-Wichers M, Elling T, de Vries-Bots AMB, et al. Convenience and satisfaction in direct oral anticoagulant-treated patients with atrial fibrillation. Res Prat Thromb Haemost. 2021;5(6):e12577.
- Wang K, et al. Impact of spontaneous extracranial bleeding events on health state utility in patients with atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial. J AM Heart Assoc. 2017;6:e006703.
- Moudallel S, van den Bemt BJF, Zwikker H, et al. Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: a cross-sectional study in patients with atrial fibrillation. Patient Educ Couns. 2021;104(1):155–162.